newsfilter
← Latest News
GlobeNewswire·

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

  • The FDA granted Orphan Drug designation to tegoprubart for preventing allograft rejection in liver transplantation.
  • Tegoprubart previously received Orphan Drug designation for preventing rejection in pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis (ALS).
  • Clinical studies in kidney transplantation showed tegoprubart could improve graft survival & function while reducing side effects from calcineurin inhibitors.
  • Eledon Pharmaceuticals plans to initiate an investigator-sponsored trial for tegoprubart in liver transplantation later in 2026.
  • Eledon is a clinical-stage biotechnology company developing tegoprubart, an anti-CD40L antibody, for immune-modulating therapies in various transplant settings & ALS.